Drugs

, Volume 39, Supplement 3, pp 53–62

Dexfenfluramine

Its Place in Weight Control
  • Paul Turner
Article

Summary

Dexfenfluramine, the dextrostereoisomer of fenfluramine, is a pure serotonin (5-hydroxytryptamine) agonist, apparently devoid of any additional antidopaminergic or sympathomimetic effects. The drug is approximately twice as effective as its racemic predecessor in reducing food intake in animals, and at a dose of 30 mg/day dexfenfluramine substantially modifies eating behaviour in man. Thus, a reduction in the motivation to eat and fewer snacking episodes were seen in volunteers treated with the drug, while total caloric and carbohydrate (but not protein) intakes were reduced in obese carbohydrate cravers. In clinical studies in obesity, dexfenfluramine combined with dietary support has produced mean weight reductions superior to those achieved with placebo over 3-month treatment periods. Importantly, the drug appears to maintain its weight-reducing effects for at least 12 months, without serious adverse effects.

Dexfenfluramine appears to possess many of the properties of an ‘ideal’ pharmacotherapeutic agent for obesity. However, further long term clinical studies are required to confirm the promising efficacy and safety data obtained to date, and to further define the most appropriate indications for its use. Ideally, the drug should be used as adjunctive treatment in the clinical management of more severe cases of obesity, which are refractory to simpler supportive measures such as dietary or psychological counselling.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Björntop P. The prevalence of obesity: complications related to the distribution of body fat. In Bender AE, Brookes LJ (Eds) Body weight control: the physiology, clinical treatment and prevention of obesity, pp. 72–80, Churchill Livingstone, Edinburgh, 1987Google Scholar
  2. Blundell JE, Hill AJ. On the mechanism of action of dexfenfluramine: effect of alliesthesia and appetite motivation in lean and obese subjects. Clinical Neuropharmacology 11(Suppl. 1): S121–S134, 1988PubMedGoogle Scholar
  3. Borsini F, Bendotti C, Alleoti A, Samanin R, Garattini S. d-Fenfluramine and d-norfenfluramine reduce food intake by acting on different serotonin mechanisms in the rat brain. Pharmacological Research Communications 14: 671–678, 1982PubMedCrossRefGoogle Scholar
  4. Borsini F, Bendotti C, Samanin R. Salbutamol, d-amphetamine and d-fenfluramine reduce sucrose intake in freely feeding rats by acting on different neurochemical mechanisms. International Journal of Obesity 9: 277–283, 1985PubMedGoogle Scholar
  5. Bray GA. To treat or not to treat — that is the question. In Bray G (Ed.) Recent advances in obesity research II, pp. 248–265, Newman, London, 1978Google Scholar
  6. Carruba MO, Ricciardi S, Spano P, Mantegazza P. Dopaminergic and serotoninergic agents differentially antagonise insulin- and 2-DG-induced hyperphagia. Life Sciences 36: 1739–1749, 1985PubMedCrossRefGoogle Scholar
  7. Enzi G, Crepaldi G, Inelmen EM, Bruni R, Baggio B. Efficacy and safety of dexfenfluramine in obese patients: a multicenter study. Clinical Neuropharmacology 11(Suppl. 1): S173–S178, 1988PubMedGoogle Scholar
  8. Even P, Nicolaidis S. Metabolic mechanism of the anorectic and leptogenic effects of the serotonin agonist fenfluramine. Appetite 7 (Suppl.): 141–163, 1986PubMedCrossRefGoogle Scholar
  9. Finer N, Craddock D, Lavielle R, Keen H. Dextrofenfluramine in the treatment of refractory obesity. Current Therapeutic Research 38: 847–854, 1985Google Scholar
  10. Finer N, Craddock D, Lavielle R, Keen H. Prolonged weight loss with dexfenfluramine treatment in obese patients. Diabete et Metabolisme 13: 598–602, 1987PubMedGoogle Scholar
  11. Garattini S. Effects of d-fenfluramine on eating disorders. In Ferrari E, Brambilla F (Eds) Disorders of eating behaviour: a psychoneuroendocrine approach (Advances in the biosciences vol. 60), pp. 327–341, Pergamon Press, Oxford, 1986Google Scholar
  12. Garattini S, Bizzi A, Caccia S, Mennini T, Samanin R. Progress in assessing the role of serotonin in the control of food intake. Clinical Neuropharmacology 11(Suppl. 1): S8–S32, 1988PubMedGoogle Scholar
  13. Garattini S, Mennini T, Bendotti C, Invernizzi R, Samanin R. Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system. Appetite 7 (Suppl.): 15–38, 1986PubMedCrossRefGoogle Scholar
  14. Garattini S, Mennini T, Samanin R. From fenfluramine to d-fenfluramine: specificity and potency of the effects on the serotoninergic system and food intake. In Wurtman JJ, Wurtman RJ (Eds) Human obesity. Annals of the New York Academy of Sciences 499: 156–166, 1987Google Scholar
  15. Garattini S, Samanin R. d-Fenfluramine and salbutamol: two drugs causing anorexia through different neurochemical mechanisms. International Journal of Obesity 8(Suppl. 1): 151–157, 1984PubMedGoogle Scholar
  16. Geelen MJH. Effects of fenfluramine on hepatic intermediary metabolism. Biochemical Pharmacology 32: 3321–3324, 1983PubMedCrossRefGoogle Scholar
  17. Guy-Grand BJP. Place of dexfenfluramine in the management of obesity. Clinical Neuropharmacology 11(Suppl. I): S216–S223, 1988PubMedGoogle Scholar
  18. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, et al. International trial of long-term dexfenfluramine in obesity. Lancet 2: 1142–1145, 1989PubMedCrossRefGoogle Scholar
  19. Hill AJ, Blundell JE. Model system for investigating the actions of anorectic drugs: effect of d-fenfluramine on food intake, nutrient selection, preferences, meal patterns, hunger and satiety in healthy human subjects. In Ferrari E, Brambilla A (Eds) Disorders of eating behaviour: a psychoneuroendocrine approach (Advances in the biosciences, vol. 60), pp. 377–389, Pergamon Press, Oxford, 1986Google Scholar
  20. Hirsh JA, Wurtman J. Effects of d or 1 isomers of fenfluramine and norfenfluramine on food choice by rats. In Garattini S, Samanin R (Eds) Anorectic agents: mechanisms of action and tolerance, pp. 159–168, Raven Press, New York, 1981Google Scholar
  21. Hoebel BG, Hernandez L, McClelland RC, Schwartz D. Dexfenfluramine and feeding reward. Clinical Neuropharmacology 11(Suppl. 1): S72–S85, 1988PubMedGoogle Scholar
  22. Le Douarec VC, Schmitt H, Laubie M. Etude pharmacologique de la fenfluramine et de ses isomères optiques. Archives Internationales de Pharmacodynamie et de Thérapie 161: 206–232, 1966PubMedGoogle Scholar
  23. Leibowitz SF, Weiss GF, Shor-Posner G. Hypothalamic serotonin: pharmacological, biochemical, and behavioural analyses of its feeding-suppressive action. Clinical Neuropharmacology 11(Suppl. 1): S51–S71, 1988PubMedGoogle Scholar
  24. Levitsky DA, Schuster JA, Stallone D, Strupp BJ. Modulation of the thermic effect of food by fenfluramine. International Journal of Obesity 10: 169–173, 1986PubMedGoogle Scholar
  25. Levitsky DA, Stallone D. Enhancement of the thermic effect of food by d-fenfluramine. Clinical Neuropharmacology 11(Suppl. 1): S90–S92, 1988PubMedGoogle Scholar
  26. O’Rourke D, Wurtman J, Brzezinski A, Abou-Nader T, Marchant P, et al. Treatment of seasonal affective disorder with d-fenfluramine. In Wurtman JJ, Wurtman RJ, (Eds) Human obesity. Annals of the New York Academy of Sciences 499: 329–330, 1987Google Scholar
  27. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 10: 241–323, 1975PubMedCrossRefGoogle Scholar
  28. Rowland NE, Carlton J. Dexfenfluramine: effects on food intake in various animal models. Clinical Neuropharmacology 11(Suppl. 1): S33–S50, 1988PubMedGoogle Scholar
  29. Russell GFM, Checkley AS, Feldman J, Eisler I. A controlled trial of d-fenfluramine in bulimia nervosa. Clinical Neuropharmacology 11(Suppl. 1): S146–S159, 1988PubMedGoogle Scholar
  30. Silverstone T, Goodall E. The efficacy and acceptability of d-fenfluramine (Isomeride) in neuroleptic induced obesity. In Ferrari E, Brambilla F (Eds) Disorders of eating behaviour: a psychoneuroendocrine approach (Advances in the biosciences, vol. 60), pp. 361–366, Pergamon Press, Oxford, 1986Google Scholar
  31. Stunkard AJ. Behavioural treatment of obesity: the first ten years. In Bray G (Ed.) Recent advances in obesity research II, pp. 205–306, Newman, London, 1978Google Scholar
  32. Stunkard AJ. Anorectic agents lower a body weight set point. Life Sciences 30: 2043–2055, 1982PubMedCrossRefGoogle Scholar
  33. Stunkard AJ, MacLaren Hume M. The result of treatment for obesity. Archives of Nutritional Medicine 103: 79–84, 1959CrossRefGoogle Scholar
  34. Turner P. Peripheral mechanism of action of fenfluramine. Current Medical Research and Opinion 6(Suppl. 1): 101–105, 1979CrossRefGoogle Scholar
  35. Turner P. Human implications from animal experiments — lessons from dexfenfluramine. Clinical Neuropharmacology 11(Suppl. 1): S113–S120, 1988PubMedGoogle Scholar
  36. Turner P, Bichi LA, Slusarczyk H, Franklin CS. The peripheral actions of antiobesity drugs. International Journal of Obesity 6: 411–415, 1982PubMedGoogle Scholar
  37. Veldhoven PV, Declerq PE, Debeer LJ, Mannderto GP. Effects of benfluorex and fenofibrate treatment on mitochondrial and peroxisomal marker enzymes in rat liver. Biochemical Pharmacology 33: 1153–1155, 1984PubMedCrossRefGoogle Scholar
  38. Wurtman JJ, Wurtman RJ. d-Fenfluramine selectively decreases carbohydrate but not protein intake in obese subjects. International Journal of Obesity 8(Suppl. 1): 79–84, 1984PubMedGoogle Scholar
  39. Wurtman JJ, Wurtman RJ, Mark S, Tsay R, Gilbert W, et al. d-Fenfluramine selectively suppresses carbohydrate snacking by obese subjects. International Journal of Eating Disorders 4: 89–99, 1985PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1990

Authors and Affiliations

  • Paul Turner
    • 1
  1. 1.Department of Clinical PharmacologySt Bartholomew’s HospitalLondonUK

Personalised recommendations